Pelvic myofascial pain syndrome;Síndrome de dolor miofascial de la cintura pélvica

Revista de la Sociedad Espanola del Dolor

Volumn 14, Issue 5, 2007, Pages 358-368

  Gil Garcia, Eduardo ^a,b   Martinez G L ^a   Aldaya, C ^a   Rodriguez M J ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b NONE   (Spain)

Author keywords

Pelvic myofascial pain s ndrome

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; DYSPOR; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

DIAGNOSTIC PROCEDURE; HUMAN; INJECTION SITE PAIN; MYOFASCIAL PAIN; PATHOGENESIS; PELVIS PAIN SYNDROME; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; VOMITING;

EID: 34447540038     PISSN: 11348046     EISSN: 11348046     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur J Pain. 2006; 26.
2. Ferreira JJ, Couto M, Costa J, Coelho M, Rosa MM, Sampaio C. Botulinum toxin for the treatment of pain syndromes. Acta Reumatol Port. 2006; 31: 49-62.
3. Monnier G, Tatu L, Michel F. New indications for botulinum toxin in rheumatology. Joint Bone Spine. 2006; 30.
4. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS.. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. 2006; 25; 241-5.
5. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006; 125: 82-8. Epub 2006 Jun 5.
6. Staud R. Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des. 2006; 12: 23-7.
7. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006; 22: 90-6.
8. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain. 2005; 118: 170-5. Epub 2005 Oct 3.
9. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005; 103: 377-83.
10. Abram SE. Does botulinum toxin have a role in the management of myofascial pain? Anesthesiology. 2005; 103: 223-4.
11. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005; 25: 604-11. Epub 2004 Sep 15.
12. McPartland JM. Travell trigger points - molecular and osteopathic perspectives. J Am Osteopath Assoc. 2004; 104: 244-9.
13. Lang A. History and uses of BOTOX (botulinum toxin type A). Lippincotts Case Manag. 2004; 9: 109-12.
14. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. 2004; 83: 198-202.
15. Cordivari C, Misra VP, Catania S, Lees AJ. New therapeutic indications for botulinum toxins. Mov Disord. 2004; 19 Suppl 8: S 157-61. Review.
16. Reilich P, Fheodoroff K, Kern U, Mense S, Seddigh S, Wissel J, Pongratz D. Consensus statement: botulinum toxin in myofascial [corrected] pain. J Neurol. 2004; 251
17. Porta M, Maggioni G. Botulinum toxin (BoNT) and back pain. J Neurol. 2004 ; 251 Suppl 1: I 15-8.
18. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004; 251 Suppl 1: I 1-7.
19. Wheeler AH. Myofascial pain disorders: theory to therapy. Drugs. 2004; 64: 45-62.
20. Raj PP. Botulinum toxin therapy in pain management. Anesthesiol Clin North America. 2003; 21: 715-31.
21. Royal MA. Botulinum toxins in pain management. Phys Med Rehabil Clin N Am. 2003; 14: 805-20.
22. Argoff CE. The Use of Botulinum Toxins for Chronic Pain and Headaches. Curr Treat Options Neurol. 2003; 5: 483-492.
23. Lang AM. A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-1 abel chart review. Clin Ther. 2003; 25: 2268-78.
24. De Andres J, Cerda-Olmedo G, Valia JC, Monsalve V, Lopez-Alarcon, Minguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. 2003; 19: 269-75.
25. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. 2003; 84: S 69-73.
26. Thant ZS, Tan EK. Emerging therapeutic applications of botulinum toxin. Med Sci Monit. 2003; 9: RA40-8. Review.
27. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. 2002; 18: 147-54.
28. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002; 6: 460-9.
29. Lang AM. Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep. 2002; 6: 355-60.
30. Criscuolo CM. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep. 2001; 5: 407-11.
31. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000; 85: 101-5.
32. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994; 59: 65-9.
33. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology. 1994; 80: 705-6.